Shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have earned an average recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $48.50.

Several brokerages recently commented on ACRS. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 12th. Zacks Investment Research raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Finally, Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Friday, June 29th.

In other news, Director Stephen A. Tullman purchased 6,250 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was acquired at an average price of $15.97 per share, with a total value of $99,812.50. Following the purchase, the director now owns 163,757 shares in the company, valued at approximately $2,615,199.29. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kamil Ali-Jackson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the sale, the insider now directly owns 82,536 shares of the company’s stock, valued at approximately $1,650,720. The disclosure for this sale can be found here. Insiders own 17.00% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its holdings in Aclaris Therapeutics by 561.0% in the 1st quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 5,531 shares during the last quarter. Summit Trail Advisors LLC lifted its holdings in Aclaris Therapeutics by 5,594.3% in the 1st quarter. Summit Trail Advisors LLC now owns 135,239 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 132,864 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Aclaris Therapeutics by 518.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 8,361 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 7,009 shares during the last quarter. Bank of Montreal Can acquired a new stake in Aclaris Therapeutics in the 2nd quarter worth approximately $159,000. Finally, Granite Investment Partners LLC acquired a new stake in Aclaris Therapeutics in the 2nd quarter worth approximately $164,000. 99.75% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ACRS traded up $0.02 on Friday, hitting $15.28. 238,152 shares of the company’s stock traded hands, compared to its average volume of 274,986. Aclaris Therapeutics has a 1 year low of $14.11 and a 1 year high of $28.93. The stock has a market cap of $495.69 million, a PE ratio of -6.10 and a beta of 1.18.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The company had revenue of $3.68 million for the quarter, compared to analysts’ expectations of $2.76 million. sell-side analysts forecast that Aclaris Therapeutics will post -4.54 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Recommended Story: Fiduciary

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.